Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Perisolv + hyaDent BG is a combination therapy used in dental and periodontal care, particularly for the non-surgical treatment of periodontitis, peri-implant mucositis, and peri-implantitis. The protocol involves sequential application of two products: - **Perisolv** is a debridement gel containing sodium hypochlorite and amino acids. It acts as a biofilm eraser by softening and degrading bacterial biofilm on tooth roots or implant surfaces, enhancing the effectiveness of mechanical debridement. - **hyaDent BG** is a sterile gel composed primarily of cross-linked hyaluronic acid (xHyA). Applied after debridement, it supports tissue regeneration by stabilizing blood clots, attracting growth factors, coordinating inflammation resolution, accelerating angiogenesis (new blood vessel formation), and providing bacteriostatic protection. This combination forms the basis of the CLEAN&SEAL concept—a clinically validated protocol designed to improve clinical outcomes in both surgical and non-surgical management of periodontal and peri-implant diseases. Clinical studies have shown that this approach leads to greater reductions in probing depth and improved healing compared to mechanical debridement alone[7][9][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Perisolv + hyaDent BG.